# Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

> **NCT02730130** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Triple Negative

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02730130
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-03
- **Primary completion:** 2017-09-26
- **Final completion:** 2022-10-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02730130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02730130, "Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02730130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*